197 related articles for article (PubMed ID: 1775850)
1. In vitro susceptibility vs. in vivo efficacy of various antimicrobial agents against the Bacteroides fragilis group.
Brook I
Rev Infect Dis; 1991; 13(6):1170-80. PubMed ID: 1775850
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
Brook I
J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
[TBL] [Abstract][Full Text] [Related]
3. Survey of Bacteroides fragilis group susceptibility patterns in Canada.
Bourgault AM; Lamothe F; Hoban DJ; Dalton MT; Kibsey PC; Harding G; Smith JA; Low DE; Gilbert H
Antimicrob Agents Chemother; 1992 Feb; 36(2):343-7. PubMed ID: 1605600
[TBL] [Abstract][Full Text] [Related]
4. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
Appelbaum PC; Spangler SK; Jacobs MR
Antimicrob Agents Chemother; 1991 Jun; 35(6):1214-8. PubMed ID: 1929264
[TBL] [Abstract][Full Text] [Related]
5. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study.
Bandoh K; Ueno K; Watanabe K; Kato N
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S382-6. PubMed ID: 8324152
[TBL] [Abstract][Full Text] [Related]
6. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.
Aldridge KE; Henderberg A; Sanders CV
J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826
[TBL] [Abstract][Full Text] [Related]
7. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns.
Aldridge KE; Ashcraft D; O'Brien M; Sanders CV
Antimicrob Agents Chemother; 2003 Jan; 47(1):148-53. PubMed ID: 12499183
[TBL] [Abstract][Full Text] [Related]
8. Bacteroides fragilis: current susceptibilities, mechanisms of drug resistance, and principles of antimicrobial therapy.
Cuchural GJ; Tally FP
Drug Intell Clin Pharm; 1986; 20(7-8):567-73. PubMed ID: 3488895
[TBL] [Abstract][Full Text] [Related]
9. Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989.
Betriu C; Cabronero C; Gomez M; Picazo JJ
Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):352-6. PubMed ID: 1396757
[TBL] [Abstract][Full Text] [Related]
10. Synergism between penicillin, clindamycin, or metronidazole and gentamicin against species of the Bacteroides melaninogenicus and Bacteroides fragilis groups.
Brook I; Coolbaugh JC; Walker RI; Weiss E
Antimicrob Agents Chemother; 1984 Jan; 25(1):71-7. PubMed ID: 6142680
[TBL] [Abstract][Full Text] [Related]
11. Activity of newer beta-lactam agents against clinical isolates of Bacteroides fragilis and other Bacteroides species.
O'Keefe JP; Venezio FR; DiVincenzo CA; Shatzer KL
Antimicrob Agents Chemother; 1987 Dec; 31(12):2002-4. PubMed ID: 3439807
[TBL] [Abstract][Full Text] [Related]
12. beta-Lactamase produced by a highly beta-lactam-resistant strain of Bacteroides fragilis: an obstacle to the chemotherapy of experimental mixed infections.
Ajiki Y; Koga T; Ohya S; Takenouchi T; Yasuda H; Watanabe K; Ueno K
J Antimicrob Chemother; 1991 Oct; 28(4):537-46. PubMed ID: 1761449
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of 10 antimicrobial agents in experimental infections with Bacteroides fragilis.
Joiner K; Lowe B; Dzink J; Bartlett JG
J Infect Dis; 1982 Apr; 145(4):561-8. PubMed ID: 7069236
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of moxalactam in an animal model of subcutaneous abscesses: penetration into infected sites and in vivo activity against Bacteroides fragilis.
Bartlett JG; Joiner KA; Dezfulian M; Marien GJ
Rev Infect Dis; 1982; 4 Suppl():S664-9. PubMed ID: 6218580
[TBL] [Abstract][Full Text] [Related]
15. Effect of prophylactic antibiotics upon mixed infections with Bacteroides fragilis.
Brook I
Surg Gynecol Obstet; 1987 Dec; 165(6):491-5. PubMed ID: 3317944
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology, antimicrobial susceptibility, pathogenicity, and significance of Bacteroides fragilis group organisms isolated at Los Angeles County-University of Southern California Medical Center.
Appleman MD; Heseltine PN; Cherubin CE
Rev Infect Dis; 1991; 13(1):12-8. PubMed ID: 2017610
[TBL] [Abstract][Full Text] [Related]
17. Relative efficacy and critical interval of antimicrobial agents in experimental infections involving bacteroides fragilis.
Bartlett JG; Dezfulian M; Joiner K
Arch Surg; 1983 Feb; 118(2):181-4. PubMed ID: 6849635
[TBL] [Abstract][Full Text] [Related]
18. In-vitro susceptibility and in-vivo efficacy of antimicrobials in the treatment of intraabdominal sepsis in mice.
Brook I; Gillmore JD
J Antimicrob Chemother; 1993 Mar; 31(3):393-401. PubMed ID: 8486573
[TBL] [Abstract][Full Text] [Related]
19. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.
Snydman DR; McDermott L; Cuchural GJ; Hecht DW; Iannini PB; Harrell LJ; Jenkins SG; O'Keefe JP; Pierson CL; Rihs JD; Yu VL; Finegold SM; Gorbach SL
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S54-65. PubMed ID: 8953108
[TBL] [Abstract][Full Text] [Related]
20. Annual incidence, epidemiology, and comparative in vitro susceptibilities to cefoxitin, cefotetan, cefmetazole, and ceftizoxime of recent community-acquired isolates of the Bacteroides fragilis group.
Goldstein EJ; Citron DM
J Clin Microbiol; 1988 Nov; 26(11):2361-6. PubMed ID: 3235664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
